Latest News

Treatment failure occurred in 46% of patients in the high-risk group vs 21% of patients in the low-risk group.

The study is intended to support potential label expansion of testosterone undecanoate in men aged 65 to 80 years with hypogonadism.

Enolen is currently under investigation in a phase 1 trial to assess its safety and efficacy in delivering enzalutamide locally into the prostate.

The phase 2 PROHEAR trial is assessing the safety and efficacy of ACOU085 in preventing ototoxic hearing loss induced by cisplatin-based chemotherapy.

The results from this study are expected to support an application to the FDA for premarket approval of the Butterfly device.

2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.

This episode delivers an empowering, forward-looking conversation on how APPs and physicians alike can lead health care transformation.

The study is being conducted as part of the landmark ProtecT trial.

Heidegger emphasizes that sexual concerns are almost never purely biological or purely psychological—they are biopsychosocial.

According to the authors, these findings support the early use of genomic testing to guide treatment decisions.

"Although social media may not be for every health care worker, I hope that moving forward, more medical content creators will collaborate with the academic medical community to shape the world for the better," writes Maheetha Bharadwaj, MD.

A recap of the FDA submissions and regulatory decisions in urology from December 2025.

In this episode, Jeremy Y.C. Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery), joins host Adam Weiner, MD, to discuss en bloc vs standard transurethral resection of bladder tumor in NMIBC.